1. Antigens from the helminth Fasciola hepatica exert antiviral effects against SARS-CoV-2 in vitro
- Author
-
Ministerio de Ciencia, Innovación y Universidades (España), Junta de Castilla y León, European Commission, Agencia Estatal de Investigación (España), Ministerio de Ciencia e Innovación (España), Ministerio de Economía y Competitividad (España), Serrat, Judit [0000-0002-1182-1088], Becerro Recio, David [0000-0001-8876-2592], González Miguel, Javier [0000-0003-4279-4761], Siles Lucas, Mar [0000-0002-1257-2562], Serrat, Judit, Francés-Gómez, Clara, Becerro Recio, David, González Miguel, Javier, Geller, Ron, Siles Lucas, Mar, Ministerio de Ciencia, Innovación y Universidades (España), Junta de Castilla y León, European Commission, Agencia Estatal de Investigación (España), Ministerio de Ciencia e Innovación (España), Ministerio de Economía y Competitividad (España), Serrat, Judit [0000-0002-1182-1088], Becerro Recio, David [0000-0001-8876-2592], González Miguel, Javier [0000-0003-4279-4761], Siles Lucas, Mar [0000-0002-1257-2562], Serrat, Judit, Francés-Gómez, Clara, Becerro Recio, David, González Miguel, Javier, Geller, Ron, and Siles Lucas, Mar
- Abstract
SARS-CoV-2, the causal agent of COVID-19, is a new coronavirus that has rapidly spread worldwide and significantly impacted human health by causing a severe acute respiratory syndrome boosted by a pulmonary hyperinflammatory response. Previous data from our lab showed that the newly excysted juveniles of the helminth parasite Fasciola hepatica (FhNEJ) modulate molecular routes within host cells related to vesicle-mediated transport and components of the innate immune response, which could potentially be relevant during viral infections. Therefore, the aim of the present study was to determine whether FhNEJ-derived molecules influence SARS-CoV-2 infection efficiency in Vero cells. Pre-treatment of Vero cells with a tegument-enriched antigenic extract of FhNEJ (FhNEJ-TEG) significantly reduced infection by both vesicular stomatitis virus particles pseudotyped with the SARS-CoV-2 Spike protein (VSV-S2) and live SARS-CoV-2. Pre-treatment of the virus itself with FhNEJ-TEG prior to infection also resulted in reduced infection efficiency similar to that obtained by remdesivir pre-treatment. Remarkably, treatment of Vero cells with FhNEJ-TEG after VSV-S2 entry also resulted in reduced infection efficiency, suggesting that FhNEJ-TEG may also affect post-entry steps of the VSV replication cycle. Altogether, our results could potentially encourage the production of FhNEJ-derived molecules in a safe, synthetic format for their application as therapeutic agents against SARS-CoV-2 and other related respiratory viruses.
- Published
- 2023